Patents Assigned to Good T Cells, Inc.
-
Patent number: 11932686Abstract: The present invention relates to a novel use of regulatory T cell-specific surface protein Lrig-1, and more specifically to an immunosuppressive agent comprising siRNA which inhibits the expression of surface protein Lrig-1. In addition, the invention relates to a method for screening an immunosuppressive agent which inhibits proteins of Lrig-1 or genes encoding the proteins. As a result, an immunosuppressive agent with low side effects and high specificity can be developed.Type: GrantFiled: July 13, 2021Date of Patent: March 19, 2024Assignee: Good T Cells, Inc.Inventor: Sang-kyou Lee
-
Patent number: 11918634Abstract: The present invention relates to a cancer-specific tumor antigen neoepitope represented by any one of SEQ ID NOs: 1 to 184, an antigen-presenting cell loaded with the neoepitope, and a method for activating T cells for cancer treatment using the antigen-presenting cell. An antigen-presenting cell, that is, a dendritic cell, loaded with a cancer-specific tumor antigen epitope provided in the present invention enables rapid and effective induction of differentiation and proliferation of cancer antigen-specific T cells, preferably memory T cells, and the memory T cells thus activated can treat a cancerous or neoplastic condition or prevent recurrence, progression, or metastasis of cancer while avoiding the defense mechanism of cancer cells.Type: GrantFiled: August 10, 2018Date of Patent: March 5, 2024Assignee: GOOD T CELLS, INC.Inventors: Jung Ho Kim, Beom Seok Kim
-
Patent number: 11890364Abstract: The present invention relates to a composition for prevention or treatment of hair loss. The composition is effectively delivered into hair papilla cells in a hair loss area, which is a target area, wherein a cytokine or enzyme highly expressed in the hair loss area causes a drug to be separated from a compound contained in the composition so that the drug effectively exhibits activity, which ultimately promotes hair growth and/or hair regrowth.Type: GrantFiled: December 3, 2018Date of Patent: February 6, 2024Assignee: Good T Cells, Inc.Inventors: Beom Seok Kim, Jung Ho Kim
-
Patent number: 11820801Abstract: The present invention relates to a fusion protein comprising an extracellular domain of leucine-rich and immunoglobulin-like domains-1 (Lrig-1) protein and an immunoglobulin Fc region. The fusion protein provided in the present invention can interact with a ligand for Lrig-1 protein, which is present on effector T cells, to inhibit the interaction between the effector T cells and regulatory T cells (Treg cells) having the Lrig-1 protein on their surface, so that activity of the regulatory T cells is inhibited and activity of the effector T cells is maintained or elevated, thereby effectively inhibiting growth of cancer cells, in particular, solid cancer cells.Type: GrantFiled: April 26, 2019Date of Patent: November 21, 2023Assignee: Good T Cells, Inc.Inventors: Jung Ho Kim, Beom Seok Kim
-
Publication number: 20230210896Abstract: The antigen-presenting cell loaded with the cancer-specific tumor antigen epitope provided in the present invention, that is, a dendritic cell enables rapid and effective induction of differentiation and proliferation of cancer antigen-specific T cells, preferably memory T cells, and the memory T cells thus activated can treat a cancerous or neoplastic condition or prevent recurrence, progression, or metastasis of cancer while avoiding the defense mechanism of cancer cells.Type: ApplicationFiled: February 7, 2020Publication date: July 6, 2023Applicant: GOOD T CELLS, INC.Inventors: Jung Ho Kim, Beom Seok Kim
-
Patent number: 11655287Abstract: The present invention relates to a novel use of regulatory T cell-specific surface protein Lrig-1, and more specifically to an immunosuppressive agent comprising siRNA which inhibits the expression of surface protein Lrig-1. In addition, the invention relates to a method for screening an immunosuppressive agent which inhibits proteins of Lrig-1 or genes encoding the proteins. As a result, an immunosuppressive agent with low side effects and high specificity can be developed.Type: GrantFiled: January 20, 2012Date of Patent: May 23, 2023Assignee: Good T Cells, Inc.Inventor: Sang-kyou Lee
-
Publication number: 20220275081Abstract: Provided herein is a binding molecule capable of specifically binding to LRIG-1 protein, which is located on the surface of a regulatory T cell. Also provided is pharmaceutical composition comprising the binding molecule. Further provided are methods of treating a cancer using the binding molecule or pharmaceutical composition disclosed herein.Type: ApplicationFiled: October 17, 2019Publication date: September 1, 2022Applicant: GOOD T CELLS, INC.Inventors: Jung Ho Kim, Beom Seok Kim
-
Publication number: 20220275080Abstract: Provided herein is a binding molecule capable of specifically binding to LRIG-1 protein, which is located on the surface of a regulatory T cell. Also provided is pharmaceutical composition comprising the binding molecule. Further provided are methods of treating an immune-related disease using the binding molecule or pharmaceutical composition disclosed herein.Type: ApplicationFiled: October 17, 2019Publication date: September 1, 2022Applicant: GOOD T CELLS, INC.Inventors: Jung Ho Kim, Beom Seok Kim
-
Patent number: 11414467Abstract: The present invention relates to a novel fusion protein comprising the transcription modulation domain of the transcription factor NF-?B subunit p65 and a protein transduction domain and to the use thereof. The fusion protein of the present invention has the effects of inhibiting the transcription of NF-?B and IL-2 by competitive inhibition and inhibiting the LPS-induced secretion of inflammatory cytokines and also inhibiting the production of IL-2, IFN-?, IL-4, IL-17A and IL-10 in splenocytes, and thus is effectively used as a composition for the prevention or treatment of a disease related to NF-?B overactivity.Type: GrantFiled: June 17, 2019Date of Patent: August 16, 2022Assignee: GOOD T CELLS, INC.Inventors: Sang-Kyou Lee, Sung-Dong Park
-
Publication number: 20220213186Abstract: The present invention relates to a composition for preventing, ameliorating, or treating a brain and nervous system disease by using a binding molecule capable of specifically binding to Lrig-1 protein which is a protein present on the surface of regulatory T cells.Type: ApplicationFiled: March 20, 2020Publication date: July 7, 2022Applicant: GOOD T CELLS, INC.Inventors: Jung Ho Kim, Beom Seok Kim
-
Patent number: 11365249Abstract: The present invention relates to a binding molecule capable of specifically binding to Lrig-1 protein, which is on the surface of regulatory T cells. The binding molecule provided in the present invention can suppress the function of regulatory T cells to effectively prevent, ameliorate, or treat cancer, particularly solid tumor. The binding molecule has advantages of more effectively targeting the Lrig-1 protein as compared with antibodies against Lrig-1 which are previously commercially available, and also possessing very good binding capacity thereto.Type: GrantFiled: April 18, 2018Date of Patent: June 21, 2022Assignee: GOOD T CELLS, INC.Inventors: Jung Ho Kim, Beom Seok Kim
-
Patent number: 11345729Abstract: The present disclosure relates to a novel recombinant BAF57 fusion protein and the use thereof as a composition capable of effectively preventing or treating inflammatory disease, immune-related disease or cancer. The fusion protein provided in the present disclosure may be delivered into cells, bind to BAF155 or other BAF complex subunit, and act as a competitive inhibitor of BAF57 present in the cell, thereby lowering the expression level of BAF57 by a protein degradation mechanism, thereby effectively preventing, ameliorating or treating various diseases such as inflammatory disease, immune-related disease or cancer.Type: GrantFiled: December 27, 2019Date of Patent: May 31, 2022Assignee: GOOD T CELLS, INC.Inventors: Jung Ho Kim, Beom Seok Kim
-
Publication number: 20220160761Abstract: The antigen-presenting cell loaded with the cancer-specific tumor antigen epitope provided in the present invention, that is, a dendritic cell enables rapid and effective induction of differentiation and proliferation of cancer antigen-specific T cells, preferably memory T cells, and the memory T cells thus activated can treat a cancerous or neoplastic condition or prevent recurrence, progression, or metastasis of cancer while avoiding the defense mechanism of cancer cells.Type: ApplicationFiled: February 7, 2020Publication date: May 26, 2022Applicant: GOOD T CELLS, INC.Inventors: Jung Ho Kim, Beom Seok Kim
-
Publication number: 20220135662Abstract: The present invention relates to a novel use of regulatory T cell-specific surface protein Lrig-1, and more specifically to an immunosuppressive agent comprising siRNA which inhibits the expression of surface protein Lrig-1. In addition, the invention relates to a method for screening an immunosuppressive agent which inhibits proteins of Lrig-1 or genes encoding the proteins. As a result, an immunosuppressive agent with low side effects and high specificity can be developed.Type: ApplicationFiled: January 13, 2022Publication date: May 5, 2022Applicant: GOOD T CELLS, INC.Inventor: Sang-kyou LEE
-
Patent number: 11279756Abstract: The present invention relates to a binding molecule capable of specifically binding to Lrig-1 protein, which is located on the surface of a regulatory T cell. The binding molecule provided in the present invention can activate the function of regulatory T cells to effectively prevent, ameliorate, or treat diseases caused by excessive activation or expression of various immune cells and inflammatory cells, for example, immune-related diseases such as autoimmune disease, graft-versus-host disease, organ transplant rejection, asthma, atopy, acute or chronic inflammatory disease, etc. In addition, the binding molecule, preferably the antibody, specific for the Lrig-1 protein according to the present invention has advantages of more effectively targeting the Lrig-1 protein as compared with antibodies against Lrig-1 which are previously commercially available, and also possessing very good binding capacity thereto.Type: GrantFiled: April 18, 2018Date of Patent: March 22, 2022Assignee: GOOD T CELLS, INC.Inventors: Jung Ho Kim, Beom Seok Kim
-
Publication number: 20210340235Abstract: The present invention relates to a novel use of regulatory T cell-specific surface protein Lrig-1, and more specifically to an immunosuppressive agent comprising siRNA which inhibits the expression of surface protein Lrig-1. In addition, the invention relates to a method for screening an immunosuppressive agent which inhibits proteins of Lrig-1 or genes encoding the proteins. As a result, an immunosuppressive agent with low side effects and high specificity can be developed.Type: ApplicationFiled: July 13, 2021Publication date: November 4, 2021Applicant: GOOD T CELLS, INC.Inventor: Sang-kyou Lee
-
Patent number: 11091538Abstract: The present invention relates to a novel use of regulatory T cell-specific surface protein Lrig-1, and more specifically to an immunosuppressive agent comprising siRNA which inhibits the expression of surface protein Lrig-1. In addition, the invention relates to a method for screening an immunosuppressive agent which inhibits proteins of Lrig-1 or genes encoding the proteins. As a result, an immunosuppressive agent with low side effects and high specificity can be developed.Type: GrantFiled: December 27, 2018Date of Patent: August 17, 2021Assignee: GOOD T CELLS, INC.Inventor: Sang-kyou Lee
-
Publication number: 20200048335Abstract: The present invention relates to a novel use of regulatory T cell-specific surface protein Lrig-1, and more specifically to an immunosuppressive agent comprising siRNA which inhibits the expression of surface protein Lrig-1. In addition, the invention relates to a method for screening an immunosuppressive agent which inhibits proteins of Lrig-1 or genes encoding the proteins. As a result, an immunosuppressive agent with low side effects and high specificity can be developed.Type: ApplicationFiled: October 2, 2019Publication date: February 13, 2020Applicant: GOOD T CELLS, INC.Inventor: Sang-Kyou LEE
-
Patent number: 10544196Abstract: The present invention relates to a composition and a fusion protein for prevention or treatment of autoimmune diseases, which contain a Smad protein, and provides a method for prevention or treatment of autoimmune diseases, including lupus nephritis and rheumatoid arthritis.Type: GrantFiled: November 3, 2016Date of Patent: January 28, 2020Assignee: Good T Cells, Inc.Inventor: Sang-Kyou Lee
-
Patent number: 10494411Abstract: The present invention relates to a novel fusion protein comprising the transcription modulation domain of the transcription factor NF-?B subunit p65 and a protein transduction domain and to the use thereof. The fusion protein of the present invention has the effects of inhibiting the transcription of NF-?B and IL-2 by competitive inhibition and inhibiting the LPS-induced secretion of inflammatory cytokines and also inhibiting the production of IL-2, IFN-?, IL-4, IL-17A and IL-10 in splenocytes, and thus is effectively used as a composition for the prevention or treatment of a disease related to NF-?B overactivity.Type: GrantFiled: November 3, 2016Date of Patent: December 3, 2019Assignee: Good T Cells, Inc.Inventors: Sang-Kyou Lee, Sung-Dong Park